Z-021

Ziprasidone hydrochloride solution

1 mg/mL ((as free base), Methanol:DMSO (80:20) (m/m)), certified reference material, ampule of 1 mL, Cerilliant^®

• Wzór empiryczny (zapis Hilla): C₂₁H₂₁ClN₄OS · HCl
• Numer CAS: 122883-93-6
• Masa cząsteczkowa: 449.40
• Numer MDL: MFCD06795476
• Kod UNSPSC: 41116107
• NACRES: NA.24

Właściwości

• klasa czystości: certified reference material
• Poziom jakości: 300
• Właściwości: Snap-N-Spike^®/Snap-N-Shoot^®
• opakowanie: ampule of 1 mL
• producent / nazwa handlowa: Cerilliant^®
• stężenie: 1 mg/mL ((as free base), Methanol:DMSO (80:20) (m/m))
• format: single component solution
• temp. przechowywania: -10 to -25°C
• InChI: 1S/C21H21ClN4OS.ClH.H2O/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21;;/h1-4,11,13H,5-10,12H2,(H,23,27);1H;1H2
• Klucz InChI: ZCBZSCBNOOIHFP-UHFFFAOYSA-N

Opis

Opis ogólny

A Certified Spiking Solution^® applicable to use in forensic drug analysis or calibrator preparation by LC/MS or GC/MS. Ziprasidone is sold under the trade names Geodon and Zeldox for treatment of schizophrenia and bipolar disorder. Recent studies have suggested that Ziprasidone may increase the risk of Type II diabetes and hyperglycemia.

Zastosowanie

• Enhanced Drug Delivery Systems: A study detailed the development of sustained-release ziprasiDonemicroparticles using Soluplus and ethyl cellulose. This formulation aims to eliminate the food effect and enhance bioavailability, marking a significant advancement in pharmaceutical formulations for schizophrenia treatment (Liu W et al., 2019).


• Targeted CNS Delivery:The study evaluated the brain-targeting and antipsychotic activities of nasally administered ziprasiDonethrough lipid-polymer hybrid nanocarriers. This novel delivery method could revolutionize treatment approaches in psychiatric medicine by enhancing drug efficacy and patient compliance in schizophrenia management (Abo El-Enin HA et al., 2023).


• Real-world Effectiveness in Bipolar Disorder:The study conducted a register-based national cohort study on the real-world effectiveness of pharmacological treatments for bipolar disorder, including ziprasidone. This research provides valuable insights into the therapeutic impacts and side effect profiles of ziprasiDonein a large patient population (Lahteenvuo M et al., 2023).

Informacje prawne

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

This page may contain text that has been machine translated.

Informacja o środkach bezpieczeństwa

• Piktogramy: GHS02,GHS06,GHS08
• Hasło ostrzegawcze: Danger
• Zwroty wskazujące rodzaj zagrożenia: H225,H301 + H311 + H331,H370
• Zwroty wskazujące środki ostrożności: P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311
• Klasyfikacja zagrożeń: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• Organy docelowe: Eyes,Central nervous system
• Kod klasy składowania: 3 - Flammable liquids
• Klasa zagrożenia wodnego (WGK): WGK 2
• Temperatura zapłonu (°F): 71.6 °F
• Temperatura zapłonu (°C): 22 °C